Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RELIEF THERAPEUTICS Holding ( (CH:RLF) ) just unveiled an update.
Relief Therapeutics Holding SA announced a joint presentation with NeuroX Group SA ahead of their anticipated business combination, expected to close in mid-December 2025. The combined entity projects significant revenue growth, aiming for over CHF 40 million in 2027 and exceeding CHF 200 million by 2031, with a normative EBITDA margin of approximately 55% by 2028. This growth is driven by the adoption of NeuroX’s digital neurotherapeutics suite, following the consolidation of MindMaze assets, positioning the company for substantial market expansion.
The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF2.50 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company focused on developing innovative treatments for rare and debilitating diseases. The company specializes in drug delivery systems and drug repurposing, targeting unmet medical needs in dermatological, metabolic, and respiratory conditions. Relief has successfully marketed several products through licensing and distribution partnerships. Headquartered in Geneva, it is listed on the SIX Swiss Exchange and quoted in the U.S. on OTCQB.
Average Trading Volume: 38,687
Technical Sentiment Signal: Sell
Current Market Cap: CHF32.24M
For an in-depth examination of RLF stock, go to TipRanks’ Overview page.